To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
Status:
Recruiting
Trial end date:
2026-07-14
Target enrollment:
Participant gender:
Summary
This is a rare disease, single-arm, open-label,multi-center, non-randomized Phase 2 clinical
study to evaluate the efficacy, safety, and pharmacokinetic characteristics of FCN-159
monotherapy in pediatric patients with refractory/recurrent Langerhans cell histiocytosis
(LCH).
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.